1581734-69-1

Usage

Uses

Used in Organic Synthesis:
(2R,3S)-1-benzyl 4-tert-butyl 3-(cyclopropylmethyl)-2-(3,3,3-5 trifluoropropyl)succinate is used as a building block in organic synthesis for the creation of more complex molecules. The presence of benzyl and tert-butyl groups allows for versatile synthetic manipulations, making it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Chemistry:
In the pharmaceutical industry, (2R,3S)-1-benzyl 4-tert-butyl 3-(cyclopropylmethyl)-2-(3,3,3-5 trifluoropropyl)succinate is used as a key intermediate in the development of new drugs. Its chiral nature and diverse functional groups enable the design of enantioselective catalysts and ligands, which are essential for the synthesis of biologically active compounds with high selectivity and potency.
Used in Industrial Applications:
The unique combination of fluorinated and cyclopropylmethyl groups in (2R,3S)-1-benzyl 4-tert-butyl 3-(cyclopropylmethyl)-2-(3,3,3-5 trifluoropropyl)succinate may confer specific chemical properties that are valuable in various industrial applications. These could include uses in materials science, such as the development of new polymers with tailored properties, or in the creation of novel catalysts for chemical processes.
Used in Research and Development:
(2R,3S)-1-benzyl 4-tert-butyl 3-(cyclopropylmethyl)-2-(3,3,3-5 trifluoropropyl)succinate is also used as a research tool in academic and industrial laboratories. Its structural diversity and potential reactivity make it an interesting subject for studies aimed at understanding new synthetic methods, exploring the biological activity of complex molecules, and investigating the effects of chirality on chemical and biological properties.

Upstream product

• 1401067-08-0 (R)-2-(2-(tert-butoxy)-2-oxoethyl)-5,5,5-trifluoropentanoic acid 
• 1581735-04-7 (R)-2-((S)-1-tert-butoxy-3-cyclopropyl-1-oxopropan-2-yl)-5,5,5-trifluoropentanoic acid 
• 100-39-0 benzyl bromide 
• 1581735-07-0 (2R,3S)-3-(tert-butoxycarbonyl)-2-(3,3,3-trifluoropropyl)hex-5-enoic acid 
• 70-25-7 N-Methyl-N'-nitro-N-nitrosoguanidine 
• 1581734-68-0 (2S,3R)-4-benzyl 1-tert-butyl 2-allyl-3-(3,3,3-trifluoropropyl)succinate 
• 186581-53-3 diazomethane 

Downstream Products

• 1581735-04-7 (R)-2-((S)-1-tert-butoxy-3-cyclopropyl-1-oxopropan-2-yl)-5,5,5-trifluoropentanoic acid 
• 1581735-06-9 (2R,3R)-1-benzyl 4-tert-butyl 3-(cyclopropylmethyl)-2-(3,3,3-trifluoropropyl)succinate 
• 1584715-30-9 (2R,3S)-3-(cyclopropylmethyl)-N₁-((R)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3,3,3-trifluoropropyl)succinamide 
• 1584715-42-3 (2S,3R)-tert-butyl 3-((9-bromo-5-(4-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(cyclopropylmethyl)-6,6,6-trifluorohexanoate 
• 1584715-89-8 (2S,3R)-tert-butyl 3-((3S)-(5-(4-chlorophenyl)-9-cyclopropyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4 ]diazepin-3-yl)carbamoyl)-2-( cyclopropylmethyl)-6,6,6-trifluorohexanoate 
• 1584715-91-2 (2S,3R)-tert-butyl 3-((3R)-(5-(4-chlorophenyl)-9-cyclopropyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4 ]diazepin-3-yl)carbamoyl)-2-( cyclopropylmethyl)-6,6,6-trifluorohexanoate 
• 1584713-87-0 (2R,3S)-3-(cyclopropylmethyl)-N-((3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2-(3,3,3-trifluoropropyl)succinamide 
• 1584715-43-4 (2S,3R)-3-(((3S)-5-(4-chlorophenyl)-9-cyclopropyl-2-oxo-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)carbamoyl)-2-(cyclopropylmethyl)-6,6,6-trifluorohexanoic acid 
• 1584714-12-4 (2R,3S)-3-(cyclopropylmethyl)-N-((3S)-9-fluoro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2-(3,3,3-trifluoropropyl)succinamide 
• 1584715-75-2 (R)-tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(((2S,3R)-2-(cyclopropylmethyl)-6,6,6-trifluoro-3-(((S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)hexanamido)thio)propanoate 
• 1584715-77-4 tert-butyl 2-((2S,3R)-2-(cyclopropylmethyl)-6,6,6-trifluoro-3-((S,Z)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)hexanamidothio)ethylcarbamate 
• 1584715-79-6 (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(((2S,3R)-2-(cyclopropylmethyl)-6,6,6-trifluoro-3-(((S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)hexanamido)thio)propanoate 
• 1584715-84-3 ((S)-3-((R)-2-((S)-1-amino-3-cyclopropyl-1-oxopropan-2-yl)-5,5,5-trifluoropentanamido)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl 1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 1584713-93-8 (2R,3S)-3-(cyclopropylmethyl)-N-((3S)-9-methoxy-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2-(3,3,3-trifluoropropyl)succinamide 

Relevant academic research and scientific papers

A Practical Approach for Enantio- and Diastereocontrol in the Synthesis of 2,3-Disubstituted Succinic Acid Esters: Synthesis of the pan-Notch Inhibitor BMS-906024

An oxidative intermolecular enolate heterocoupling reaction was employed for the synthesis of anti-2,3-disubstituted succinic acid mono- and differentially protected diesters. Tactical approaches to access all the diastereomers are discussed. The method w

TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS

Disclosed are compounds of Formula (I), wherein: X is O or -NR3; R1 is -CH2CH2CH3, -CH2CF3, -CH2CH2CF3, -CH2CF2CH3, -CH2CH2CH2CF3, -CH2CH2CF2CH3, -CH2CH(CH3)CF3, -CH2CH2CH2F, or CH2(cyclopropyl); R2 is -CH2CH2CH3, -CH2CF3, -CH2CH2CF3, -CH2CF2CH3, -CH2CH2CH2CF3, -CH2CH2CH2F, -CH2CH(CH3)CF3, CH2CH2CF2CH3, -CH2(cyclopropyl), -CH(CH3)(cyclopropyl), phenyl, fluorophenyl, chlorophenyl, trifluorophenyl, methylisoxazolyl, pyridinyl, formula (i), formula (ii), formula (iii), formula (iv) or formula (v); Ring A is phenyl or pyridinyl; and R3, Ra, Rb, Rc, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I) and/or salts thereof: (I) wherein: R1 is CH2CH2CF3; R2 is CH2(cyclopropyl), CH(CH3)(cyclopropyl), or CH2CH2CH3/

SUBSTITUTED 1,5-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I): wherein: R1 is CH2CH2CF3; R2 is CH2CH2CF3, CH2(cyclopropyl), or phenyl; R3 is H or CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.